Page last updated: 2024-11-04

alpha-glycerophosphoric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID754
CHEMBL ID358320
CHEBI ID14336
CHEBI ID15943
SCHEMBL ID7340
MeSH IDM0094376

Synonyms (60)

Synonym
glyceryl 1-phosphate
1-glycerophosphate
nsc-9231
glycerol, 1-(dihydrogen phosphate)
1,3-propanetriol, 1-(dihydrogen phosphate)
glycerol .alpha.-phosphate
.alpha.-phosphoglycerol
.alpha.-glycerophosphoric acid
1-glycerophosphoric acid
3-glycerophosphate
.alpha.-glycerophosphate
nsc9231 ,
dl-glycerol 1-phosphate
dl-glyceryl 1-phosphate
glycerophosphoric acid
C03189
rac-glycerol 1-phosphate
57-03-4
alpha-glycerophosphoric acid
dl-glycerol 3-phosphate
glycerol 1-(dihydrogen phosphate)
d,l-alpha-glycerol-phosphate
glycerol alpha-phosphate
CHEBI:14336 ,
1-phosphoglycerol
alpha-phosphoglycerol
2,3-dihydroxypropyl dihydrogen phosphate
2,3-hydroxy-1-propyl dihydrogen phosphate
1,2,3-propanetriol, 1-(dihydrogen phosphate)
A4A70DCA-5E3D-42CA-A01B-1D33D3F925CB
CHEBI:15943
CHEMBL358320
glycerophosphoric acid, alpha-
1509-81-5
BMSE000193
glycerol, 1-(dihydrogen phosphate) (8ci)
AKOS006242578
nsc 9231
einecs 200-307-1
9nti6p3o4x ,
unii-9nti6p3o4x
FT-0626751
EPITOPE ID:130695
gtpl4740
(2,3-dihydroxypropoxy)phosphonic acid
AWUCVROLDVIAJX-UHFFFAOYSA-N
SCHEMBL7340
glycerophosphoric acid [mi]
1,2,3-propanetriol,phosphate
W-110450
DTXSID6023105
mfcd00152510
SR-01000945006-1
sr-01000945006
rac-glycerol 1-phosphate sodium salt hydrate, >=95.0% (tlc)
glycerol-alpha-phosphate
Q2739882
CS-0179693
(rac)-sn-glycerol 3-phosphate
HY-113128C

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" After drug administration, a total of 15 subjects reported the occurrence of at least 1 treatment emergent adverse event (AE)."( Glycerophosphate is interchangeable with inorganic phosphate in terms of safety and serum pharmacokinetics.
Bark, S; Grossmann, M; Hochfeld, O; Joukhadar, C; Rothenburger, M; Straatsma, H; Topp, H; Westphal, M, 2011
)
0.37
" No adverse events were reported."( Early Hypophosphatemia in High-Risk Preterm Infants: Efficacy and Safety of Sodium Glycerophosphate From First Day on Parenteral Nutrition.
Bustos Lozano, G; Chumillas Calzada, S; García Soria, CE; Pallás-Alonso, CR; Pinilla Martín, MT; Soriano-Ramos, M, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
"The primary aim of the present investigation was to determine and compare the pharmacokinetic (PK) profiles of inorganic phosphate in serum and urine after intravenous administration of sodium glycerophosphate and inorganic sodium phosphate."( Glycerophosphate is interchangeable with inorganic phosphate in terms of safety and serum pharmacokinetics.
Bark, S; Grossmann, M; Hochfeld, O; Joukhadar, C; Rothenburger, M; Straatsma, H; Topp, H; Westphal, M, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" Choline phosphate decreased rapidly during dosing in all but the 5% group, but no changes in those levels were observed after 2 weeks of galactose dosing."( Organophosphate metabolic changes in the rat lens during the development of galactose-induced cataract.
Igarashi, H; Sakagami, K; Tanaka, K; Yoshida, A, 1999
)
0.3
"The solubility of inorganic calcium and phosphate in parenteral solutions can be complicated in pediatrics due to the dosing of calcium and phosphorus at the saturation point."( Physical Compatibility of Sodium Glycerophosphate and Calcium Gluconate in Pediatric Parenteral Nutrition Solutions.
Anderson, C; MacKay, M, 2015
)
0.42
" Notably, the effects of glycerol application on G3P and 18:1 fatty acid content, and gene expression levels, in cacao leaves were dosage dependent."( Application of glycerol as a foliar spray activates the defence response and enhances disease resistance of Theobroma cacao.
Guiltinan, MJ; Maximova, SN; Smith, P; Zhang, Y, 2015
)
0.42
" Concurrent dosing of intravenous products via y-site administration with PN can alter the chemical balance of the solution and modify solubility."( Avoidance of Overt Precipitation and Patient Harm Following Errant Y-Site Administration of Calcium Chloride and Parenteral Nutrition Compounded With Sodium Glycerophosphate.
Anderson, C; Boehme, S; Cash, J; Stidham, C, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
glycerol monophosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID213527Compound was tested for binding affinity against tryptophan synthase2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water.
AID221770Effective concentration to activate gammadelta T cells2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Quantitative structure--activity relations for gammadelta T cell activation by phosphoantigens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (576)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990206 (35.76)18.7374
1990's134 (23.26)18.2507
2000's92 (15.97)29.6817
2010's114 (19.79)24.3611
2020's30 (5.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.13 (24.57)
Research Supply Index6.40 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.50%)5.53%
Reviews24 (4.03%)6.00%
Case Studies3 (0.50%)4.05%
Observational1 (0.17%)0.25%
Other565 (94.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]